Diversity and Function of Mutations in P450 Oxidoreductase in Patients with Antley-Bixler Syndrome and Disordered Steroidogenesis
Open accessThe DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
Abstract
P450 oxidoreductase (POR) is the obligatory flavoprotein intermediate that transfers electrons from reduced nicotinamide adenine dinucleotide phosphate (NADPH) to all microsomal cytochrome P450 enzymes. Although mouse Por gene ablation causes embryonic lethality, POR missense mutations cause disordered steroidogenesis, ambiguous genitalia, and Antley-Bixler syndrome (ABS), which has also been attributed to fibroblast growth factor receptor 2 (FGFR2) mutations. We sequenced the POR gene and FGFR2 exons 8 and 10 in 32 individuals with ABS and/or hormonal findings that suggested POR deficiency. POR and FGFR2 mutations segregated completely. Fifteen patients carried POR mutations on both alleles, 4 carried mutations on only one allele, 10 carried FGFR2 or FGFR3 mutations, and 3 patients carried no mutations. The 34 affected POR alleles included 10 with A287P (all from whites) and 7 with R457H (four Japanese, one African, two whites); 17 of the 34 alleles carried 16 "private" mutations, including 9 missense and 7 frameshift mutations. These 11 missense mutations, plus 10 others found in databases or reported elsewhere, were recreated by site-directed mutagenesis and were assessed by four assays: reduction of cytochrome c, oxidation of NADPH, support of 17alpha-hydroxylase activity, and support of 17,20 lyase using human P450c17. Assays that were based on cytochrome c, which is not a physiologic substrate for POR, correlated poorly with clinical phenotype, but assays that were base…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Whereas most genetically determined craniosynostosis is characterised by dominant inheritance, Antley-Bixler syndrome (features include disordered sex development and radio-humeral synostosis; mutation in POR encoding cytochrome P450 oxidoreductase) 35 and Carpenter syndrome (with polysyndactyly; mutation in RAB23 encoding RAB23, member of RAS oncogene family) 36 are recessive disorders.”
From Craniosynostosis (2011) · cites this paper as [35]
In the citing paper
“These mutations demonstrate pathogenic roles for steroid metabolism and hedgehog (or possibly Wnt) signalling in cranial suture development, both of which are at present poorly understood.”
From Craniosynostosis (2011) · cites this paper as [35]
In the citing paper
“POR is located in the endoplasmic reticulum of the cells, where it operates as an electron donor for the cytochromes P450, heme oxygenase, squalene monooxygenase, and other redox partners [2,3,4].”
From Loss of Protein Stability and Function Caused by P228L Variation in NADPH-Cytochrome P450 Reductase Linked to Lower Testosterone Levels (2022) · cites this paper as [4]
In the citing paper
“Considering all available data from previous reports [4,46,47] and multiple functional assays described in this manuscript, we suggest that rs17853284, the variant causing amino acid change P228L in POR, is a disease-causing variant, whose effect will be prominent when present together with another variant of POR on the second allele that has a severe impact on POR activities.”
From Loss of Protein Stability and Function Caused by P228L Variation in NADPH-Cytochrome P450 Reductase Linked to Lower Testosterone Levels (2022) · cites this paper as [4]
In the citing paper
“Before our study only two p.A287P homozygous patients have been described; one with an unclear karyotype and genital appearance (7) and the other with ambiguous genitalia and 46,XY DSD (3).”
From Genotype-Phenotype Analysis in Congenital Adrenal Hyperplasia due to P450 Oxidoreductase Deficiency (2012) · cites this paper as [7]
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Thompson, J. D., Higgins, D. G., & Gibson, T. J. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.22.4673 · Cited by 64,617 · cited 2×
“The POR sequences from human, rat, Xenopus, Drosophila, and yeast were aligned with ClustalW (Thompson et al. 1994), and sequences were displayed and ed-”
MethodComparative Protein Modelling by Satisfaction of Spatial Restraints
Šali, A., & Blundell, T. L. (1993) · Journal of Molecular Biology · doi:10.1006/jmbi.1993.1626 · Cited by 12,977
The Carbon Monoxide-binding Pigment of Liver Microsomes
Omura, T., & Sato, R. (1964) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)82244-3 · Cited by 11,781
SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling
Guex, N., & Peitsch, M. C. (1997) · ELECTROPHORESIS · doi:10.1002/elps.1150181505 · Cited by 11,241
Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase
Bredt, D. S., Hwang, P. M., Glatt, C. E., Lowenstein, C., Reed, R. R., & Snyder, S. H. (1991) · Nature · doi:10.1038/351714a0 · Cited by 2,354
Modeling of loops in protein structures
Fiser, A., Do, R. K. G., & Šali, A. (2000) · Protein Science · doi:10.1110/ps.9.9.1753 · Cited by 2,116 · cited 1×
“Molecular modeling of human POR was performed by MODELLER (Sali and Blundell 1993; Fiser et al. 2000), which uses satisfaction of spatial restraints for comparative modeling of proteins.”
MethodMiroux, B., & Walker, J. E. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0399 · Cited by 1,959
Congenital Adrenal Hyperplasia
(1987) · New England Journal of Medicine · doi:10.1056/nejm198711263172211 · Cited by 1,409
Congenital adrenal hyperplasia
Speiser, P. W., & White, P. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021561 · Cited by 1,405
Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome
Wilkie, A. O. M., Slaney, S. F., Oldridge, M., Poole, M. D., Ashworth, G. J., Hockley, A. D., Hayward, R. D., David, D. J., Pulleyn, L. J., Rutland, P., et al. (1995) · Nature Genetics · doi:10.1038/ng0295-165 · Cited by 935
Self-citation
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
“In recent years rare POR missense mutations in humans were discovered that cause disordered steroidogenesis, ambiguous genitalia, and Antley–Bixler syndrome (Flück et al., 2004; Huang et al., 2005; Flück et al., 2008).”
BackgroundThe Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
Self-citationYan, B., Ai, Y., Sun, Q., Ma, Y., Cao, Y., Wang, J., Zhang, Z., & Wang, X. (2021) · Molecular Cell · doi:10.1016/j.molcel.2020.11.024 · Cited by 617
Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
Self-citationHuman cytochromes P450 in health and disease
Nebert, D. W., Wikvall, K., & Miller, W. L. (2013) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2012.0431 · Cited by 505
Self-citationJohnson, D., & Wilkie, A. O. M. (2011) · European Journal of Human Genetics · doi:10.1038/ejhg.2010.235 · Cited by 499
Malformation syndromes caused by disorders of cholesterol synthesis
Porter, F. D., & Herman, G. E. (2011) · Journal of Lipid Research · doi:10.1194/jlr.r009548 · Cited by 473
Zouboulis, C., Chen, W.-C., Thornton, M., Qin, K., & Rosenfield, R. (2007) · Hormone and Metabolic Research · doi:10.1055/s-2007-961807 · Cited by 379
Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine
Ahmed, S., Zhou, Z., Zhou, J., & Chen, S.-Q. (2016) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2016.03.008 · Cited by 371
The new bone biology: Pathologic, molecular, and clinical correlates
Cohen Jr., M. M. (2006) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.31368 · Cited by 335
Minireview: Regulation of Steroidogenesis by Electron Transfer
Miller, W. L. (2005) · Endocrinology · doi:10.1210/en.2005-0096 · Cited by 324
Self-citationGenetics of congenital adrenal hyperplasia
Krone, N., & Arlt, W. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.10.014 · Cited by 312
Iyanagi, T. (2007) · International Review of Cytology · doi:10.1016/s0074-7696(06)60002-8 · Cited by 290
NADPH P450 oxidoreductase: Structure, function, and pathology of diseases
Pandey, A. V., & Flück, C. E. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.010 · Cited by 279
Self-citationJenkins, D., Seelow, D., Jehee, F. S., Perlyn, C. A., Alonso, L. G., Bueno, D. F., Donnai, D., Josifiova, D., Mathijssen, I. M. J., Morton, J. E. V., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/518047 · Cited by 276
Steroid 17-hydroxylase and 17,20-lyase deficiencies, genetic and pharmacologic
Auchus, R. J. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.02.002 · Cited by 229
Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the “Missing Heritability” Problem
Klein, K., & Zanger, U. M. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00012 · Cited by 220
46,XY disorders of sex development (DSD)
Mendonca, B. B., Domenice, S., Arnhold, I. J. P., & Costa, E. M. F. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03392.x · Cited by 204
Huang, N., Agrawal, V., Giacomini, K. M., & Miller, W. L. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711621105 · Cited by 198
Self-citationŠrejber, M., Navrátilová, V., Paloncýová, M., Bazgier, V., Berka, K., Anzenbacher, P., & Otyepka, M. (2018) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2018.03.002 · Cited by 190
Alternative (backdoor) androgen production and masculinization in the human fetus
O’Shaughnessy, P. J., Antignac, J. P., Le Bizec, B., Morvan, M.-L., Svechnikov, K., Söder, O., Savchuk, I., Monteiro, A., Soffientini, U., Johnston, Z. C., et al. (2019) · PLOS Biology · doi:10.1371/journal.pbio.3000002 · Cited by 177
Genotype-Phenotype Analysis in Congenital Adrenal Hyperplasia due to P450 Oxidoreductase Deficiency
Krone, N., Reisch, N., Idkowiak, J., Dhir, V., Ivison, H. E., Hughes, B. A., Rose, I. T., O'Neil, D. M., Vijzelaar, R., Smith, M. J., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0640 · Cited by 163
Hughes, I. A., & Deeb, A. (2006) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2006.11.003 · Cited by 159
Homma, K., Hasegawa, T., Nagai, T., Adachi, M., Horikawa, R., Fujiwara, I., Tajima, T., Takeda, R., Fukami, M., & Ogata, T. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2460 · Cited by 153
NADPH–Cytochrome P450 Oxidoreductase: Roles in Physiology, Pharmacology, and Toxicology
Riddick, D. S., Ding, X., Wolf, C. R., Porter, T. D., Pandey, A. V., Zhang, Q., Gu, J., Finn, R. D., Ronseaux, S., McLaughlin, L. A., et al. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.048991 · Cited by 164
Self-citationThe syndrome of 17,20 lyase deficiency
Miller, W. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2161 · Cited by 143
MECHANISMS IN ENDOCRINOLOGY: Rare defects in adrenal steroidogenesis
Miller, W. L. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0279 · Cited by 136
Self-citationModulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase
Pandey, A. V., Kempná, P., Hofer, G., Mullis, P. E., & Flück, C. E. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0245 · Cited by 132
Self-citationCongenital adrenal hyperplasia and P450 oxidoreductase deficiency
Krone, N., Dhir, V., Ivison, H. E., & Arlt, W. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02740.x · Cited by 131
Genetic advances in craniosynostosis
Lattanzi, W., Barba, M., Di Pietro, L., & Boyadjiev, S. A. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38159 · Cited by 129
“It is worth mentioning that a similar phenotype, without genital defects, has been attributed to heterozygous FGFR2 or FGFR3 mutations (Huang et al., 2005).”
BackgroundAndrogen synthesis in adrenarche
Miller, W. L. (2009) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-008-9102-4 · Cited by 127
Self-citationGomes, A. M., Winter, S., Klein, K., Turpeinen, M., Schaeffeler, E., Schwab, M., & Zanger, U. M. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.7 · Cited by 125
Fukami, M., Nishimura, G., Homma, K., Nagai, T., Hanaki, K., Uematsu, A., Ishii, T., Numakura, C., Sawada, H., Nakacho, M., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2816 · Cited by 117
Agrawal, V., Huang, N., & Miller, W. L. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32830054ac · Cited by 117
Self-citationNADPH–cytochrome P450 oxidoreductase: Prototypic member of the diflavin reductase family
Iyanagi, T., Xia, C., & Kim, J.-J. P. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.09.002 · Cited by 117
Genetic and clinical features of P450 oxidoreductase deficiency
Scott, R. R., & Miller, W. L. (2008) · Hormone Research in Paediatrics · doi:10.1159/000114857 · Cited by 115
Self-citationOneda, B., Crettol, S., Sirot, E. J., Bochud, M., Ansermot, N., & Eap, C. B. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833225e7 · Cited by 115
Structural basis for human NADPH-cytochrome P450 oxidoreductase deficiency
Xia, C., Panda, S. P., Marohnic, C. C., Martásek, P., Masters, B. S., & Kim, J.-J. P. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106632108 · Cited by 115
Fukami, M., Homma, K., Hasegawa, T., & Ogata, T. (2013) · Developmental Dynamics · doi:10.1002/dvdy.23892 · Cited by 114
Isolated 17,20-lyase deficiency due to the cytochrome b5 mutation W27X
Kok, R. C., Timmerman, M. A., Wolffenbuttel, K. P., Drop, S. L. S., & de Jong, F. H. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1745 · Cited by 111
Plasticity of specialized metabolism as mediated by dynamic metabolons
Laursen, T., Møller, B. L., & Bassard, J.-É. (2014) · Trends in Plant Science · doi:10.1016/j.tplants.2014.11.002 · Cited by 118
Clinical dividends from the molecular genetic diagnosis of craniosynostosis
Wilkie, A. O. M., Bochukova, E. G., Hansen, R. M. S., Taylor, I. B., Rannan‐Eliya, S. V., Byren, J. C., Wall, S. A., Ramos, L., Venâncio, M., Hurst, J. A., et al. (2006) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.31366 · Cited by 107
Formation of P450·P450 complexes and their effect on P450 function
Reed, J. R., & Backes, W. L. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.11.009 · Cited by 105
Agrawal, V., Choi, J. H., Giacomini, K. M., & Miller, W. L. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833e0cb5 · Cited by 104
Self-citationThe evolving role of genetic tests in reproductive medicine
Cariati, F., D’Argenio, V., & Tomaiuolo, R. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2019-8 · Cited by 116
Role of Protein–Protein Interactions in Cytochrome P450-Mediated Drug Metabolism and Toxicity
Kandel, S. E., & Lampe, J. N. (2014) · Chemical Research in Toxicology · doi:10.1021/tx500203s · Cited by 116
Closing the Gap: Genetic and Genomic Continuum from Syndromic to Nonsyndromic Craniosynostoses
Heuzé, Y., Holmes, G., Peter, I., Richtsmeier, J. T., & Jabs, E. W. (2014) · Current Genetic Medicine Reports · doi:10.1007/s40142-014-0042-x · Cited by 99
Self-citationHart, S. N., Wang, S., Nakamoto, K., Wesselman, C., Li, Y., & Zhong, X.-B. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f2f121 · Cited by 98
Genetics of Congenital Adrenal Hyperplasia
Hannah-Shmouni, F., Chen, W., & Merke, D. P. (2017) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.01.008 · Cited by 97
Recent insights into the Smith–Lemli–Opitz syndrome
Yu, H., & Patel, S. (2005) · Clinical Genetics · doi:10.1111/j.1399-0004.2005.00515.x · Cited by 97
Hershkovitz, E., Parvari, R., Wudy, S. A., Hartmann, M. F., Gomes, L. G., Loewental, N., & Miller, W. L. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0051 · Cited by 95
Self-citationPharmacogenomics of human P450 oxidoreductase
Pandey, A. V., & Sproll, P. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00103 · Cited by 92
“Frontiers in Pharmacology | Pharmacogenetics and Pharmacogenomics May 2014 | Volume 5 | Article 103 | 2 is close to FMN binding site but shows more than 50% of WT activity (Huang et al., 2005).”
BackgroundMethodInfluentialSelf-citationExtraadrenal 21-Hydroxylation by CYP2C19 and CYP3A4: Effect on 21-Hydroxylase Deficiency
Gomes, L. G., Huang, N., Agrawal, V., Mendonça, B. B., Bachega, T. A. S. S., & Miller, W. L. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1174 · Cited by 91
Self-citationClinical dividends from the molecular genetic diagnosis of craniosynostosis†
Wilkie, A. O. M., Bochukova, E. G., Hansen, R. M. S., Taylor, I. B., Rannan‐Eliya, S. V., Byren, J. C., Wall, S. A., Ramos, L., Venâncio, M., Hurst, J. A., et al. (2007) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.31905 · Cited by 87
Clinical, genetic and enzymatic characterization of P450 oxidoreductase deficiency in four patients
Sahakitrungruang, T., Huang, N., Tee, M. K., Agrawal, V., Russell, W. E., Crock, P., Murphy, N., Migeon, C. J., & Miller, W. L. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1460 · Cited by 82
Self-citationMonogenic disorders of adrenal steroidogenesis
Baranowski, E. S., Arlt, W., & Idkowiak, J. (2018) · Hormone Research in Paediatrics · doi:10.1159/000488034 · Cited by 79
Fukami, M., Hasegawa, T., Horikawa, R., Ohashi, T., Nishimura, G., Homma, K., & Ogata, T. (2006) · Pediatric Research · doi:10.1203/01.pdr.0000195825.31504.28 · Cited by 79
“Clinical features in cases one through three would primarily be compatible with R457H retaining some residual activity (1,2,6) Since phenotypic severity is known to roughly correlate with residual POR activity (6), this would explain the absent or mild nondiagnostic skeletal lesion in cases one through three, the lack…”
BackgroundInfluentialP450 Oxidoreductase deficiency: Analysis of mutations and polymorphisms
Burkhard, F. Z., Parween, S., Udhane, S. S., Flück, C. E., & Pandey, A. V. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.04.003 · Cited by 79
Self-citationScott, R. R., Gomes, L. G., Huang, N., Van Vliet, G., & Miller, W. L. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2345 · Cited by 79
Self-citationDifferential Inhibition of CYP17A1 and CYP21A2 Activities by the P450 Oxidoreductase Mutant A287P
Dhir, V., Ivison, H. E., Krone, N., Shackleton, C. H. L., Doherty, A. J., Stewart, P. M., & Arlt, W. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0066 · Cited by 78
46,XY DSD due to impaired androgen production
Mendonca, B. B., Costa, E. M. F., Belgorosky, A., Rivarola, M. A., & Domenice, S. (2010) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.11.003 · Cited by 78
Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro
Sandee, D., Morrissey, K., Agrawal, V., Tam, H. K., Kramer, M. A., Tracy, T. S., Giacomini, K. M., & Miller, W. L. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833f4f9b · Cited by 74
Self-citationAlternative pathway androgen biosynthesis and human fetal female virilization
Reisch, N., Taylor, A. E., Nogueira, E. F., Asby, D. J., Dhir, V., Berry, A., Krone, N., Auchus, R. J., Shackleton, C. H. L., Hanley, N. A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1906623116 · Cited by 70
The next 150 years of congenital adrenal hyperplasia
Turcu, A. F., & Auchus, R. J. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.05.013 · Cited by 70
Prenatal diagnosis of congenital adrenal hyperplasia caused by P450 oxidoreductase deficiency
Reisch, N., Idkowiak, J., Hughes, B. A., Ivison, H. E., Abdul-Rahman, O. A., Hendon, L. G., Olney, A. H., Nielsen, S., Harrison, R., Blair, E. M., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3449 · Cited by 67
“Distinct POR mutations can differentially affect the activities of electron-accepting CYP enzymes, a likely explanation for the observed phenotypic variability (5, 14–16).”
Consequences of POR mutations and polymorphisms
Miller, W. L., Agrawal, V., Sandee, D., Tee, M. K., Huang, N., Choi, J. H., Morrissey, K., & Giacomini, K. M. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.10.022 · Cited by 88
Self-citationCraniosynostosis as a clinical and diagnostic problem: molecular pathology and genetic counseling
Kutkowska‐Kaźmierczak, A., Goś, M., & Obersztyn, E. (2018) · Journal of Applied Genetics · doi:10.1007/s13353-017-0423-4 · Cited by 74
Weng, Y., Dirusso, C., Reilly, A. A., Black, P. N., & Ding, X. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504447200 · Cited by 73
Naffin-Olivos, J. L., & Auchus, R. J. (2006) · Biochemistry · doi:10.1021/bi051623y · Cited by 66
Molecular Basis for Endocrine Disruption by Pesticides Targeting Aromatase and Estrogen Receptor
Zhang, C., Schilirò, T., Gea, M., Bianchi, S., Spinello, A., Magistrato, A., Gilardi, G., & Nardo, G. D. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17165664 · Cited by 74
Sheng, L., Ding, X., Ferguson, M., McCallister, M., Rhoades, R., Maguire, M., Ramesh, A., Aschner, M., Campbell, D., Levitt, P., et al. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq304 · Cited by 63
46,XX DSD: the masculinised female
Auchus, R. J., & Chang, A. Y. (2010) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.11.001 · Cited by 66
P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity
Hart, S. N., & Zhong, X.-B. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.4.439 · Cited by 70
Electron Transfer Partners of Cytochrome P450
Waskell, L. A., & Kim, J. P. (2015) · Springer eBooks · doi:10.1007/978-3-319-12108-6_2 · Cited by 87
Flück, C. E., Mullis, P. E., & Pandey, A. V. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.09.035 · Cited by 59
Self-citationCongenital adrenal hyperplasia: focus on the molecular basis of 21-hydroxylase deficiency
Gonçalves, J., Friães, A., & Moura, L. (2007) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399407000300 · Cited by 60
Samandari, E., Kempná, P., Nuoffer, J., Hofer, G., Mullis, P. E., & Flück, C. E. (2007) · Journal of Endocrinology · doi:10.1677/joe-07-0166 · Cited by 67
Self-citationBaronio, F., Ortolano, R., Menabò, S., Cassio, A., Baldazzi, L., Natale, V. D., Tonti, G., Vestrucci, B., & Balsamo, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184605 · Cited by 60
Idkowiak, J., O'Riordan, S., Reisch, N., Malunowicz, E. M., Collins, F., Kerstens, M. N., Köhler, B., Graul-Neumann, L. M., Szarras-Czapnik, M., Dattani, M., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1607 · Cited by 64
Structure and function of NADPH-cytochrome P450 reductase and nitric oxide synthase reductase domain
Iyanagi, T. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.043 · Cited by 71
Marohnic, C. C., Panda, S. P., Martásek, P., & Masters, B. S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m607095200 · Cited by 57
P450 oxidoreductase deficiency: a new form of congenital adrenal hyperplasia
Flück, C. E., & Miller, W. L. (2006) · Current Opinion in Pediatrics · doi:10.1097/01.mop.0000236395.71956.5c · Cited by 57
Self-citationFukami, M., & Ogata, T. (2014) · Pediatrics International · doi:10.1111/ped.12518 · Cited by 56
Tee, M. K., Dong, Q., & Miller, W. L. (2008) · Endocrinology · doi:10.1210/en.2007-1527 · Cited by 55
Self-citationFlück, C. E., Nicolo, C., & Pandey, A. V. (2007) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2007.00520.x · Cited by 55
Self-citationGenetic variation in human P450 oxidoreductase
Miller, W. L., Huang, N., Agrawal, V., & Giacomini, K. M. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.09.017 · Cited by 54
Self-citationThe journey from NADPH-cytochrome P450 oxidoreductase to nitric oxide synthases
Masters, B. S. S. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.165 · Cited by 59
Disorders of Androgen Synthesis – from Cholesterol to Dehydroepiandrosterone
Miller, W. L. (2005) · Medical Principles and Practice · doi:10.1159/000086185 · Cited by 61
Self-citationThe common P450 oxidoreductase variant A503V is not a modifier gene for 21-hydroxylase deficiency
Gomes, L. G., Huang, N., Agrawal, V., Mendonça, B. B., Bachega, T. A. S. S., & Miller, W. L. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0304 · Cited by 52
Self-citation46,XY Disorders of Sexual Development
Domenice, S., Arnhold, I. J. P., Costa, E. M. F., & Mendonca, B. B. (2013) · Europe PMC (PubMed Central) · Cited by 52
The post-translational regulation of 17,20 lyase activity
Miller, W. L., & Tee, M. K. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.09.010 · Cited by 56
Self-citationThe Adrenal Cortex and its Disorders
Miller, W. L. (2009) · Brook's Clinical Pediatric Endocrinology · doi:10.1002/9781444316728.ch13 · Cited by 50
Self-citationClinical and Biochemical Consequences of P450 Oxidoreductase Deficiency
Flück, C. E., & Pandey, A. V. (2011) · Endocrine Development · doi:10.1159/000321221 · Cited by 52
Self-citationKranendonk, M., Marohnic, C. C., Panda, S. P., Duarte, M. P., Oliveira, J. S., Masters, B. S. S., & Rueff, J. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.04.014 · Cited by 60
Marohnic, C. C., Panda, S. P., McCammon, K. M., Rueff, J., Masters, B. S. S., & Kranendonk, M. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.030445 · Cited by 58
Laursen, T., Singha, A., Rantzau, N., Tutkus, M., Borch, J., Hedegård, P., Stamou, D. G., Møller, B. L., & Hatzakis, N. S. (2013) · ACS Chemical Biology · doi:10.1021/cb400708v · Cited by 53
Restoration of mutant cytochrome P450 reductase activity by external flavin
Nicolo, C., Flück, C. E., Mullis, P. E., & Pandey, A. V. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.02.024 · Cited by 50
Self-citationCharacterization of the first FGFRL1 mutation identified in a craniosynostosis patient
Rieckmann, T., Zhuang, L., Flück, C. E., & Trüeb, B. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.11.006 · Cited by 45
Self-citationTee, M. K., Huang, N., Damm, I., & Miller, W. L. (2011) · Molecular Endocrinology · doi:10.1210/me.2010-0236 · Cited by 46
Self-citationZhang, X., Li, L., Ding, X., & Kaminsky, L. S. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.038836 · Cited by 51
Metadata
- Authors
- Huang, N., Pandey, A. V., Agrawal, V., Reardon, W., Lapunzina, P. D., Mowat, D., Jabs, E. W., Vliet, G. V., Sack, J., Flück, C. E., & Miller, W. L.
- Affiliations
- University of California, San Francisco (US)
- Children's Health Ireland at Crumlin (IE)
- Hospital Universitario La Paz (ES)
- Sydney Children's Hospital (AU)
- Johns Hopkins University (US)
- Université de Montréal (CA)
- Tel Aviv University (IL)
- University Children’s Hospital Bern (CH)
- ORCID
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 2005-05
- Volume
- 76
- Issue
- 5
- Pages
- 729-749
- ISSN
- 0002-9297 (ISSN-L)
- PMC
- PMC1199364
- OpenAlex
- W2062798854
- Semantic Scholar
- 892a16ff5112b5c86510eedcdee62d1812e75a79
- Cited by
- 336
- References
- 99
- Citations by year
- 2026: 9 · 2025: 4 · 2024: 10 · 2023: 10 · 2022: 13 · 2021: 9 · 2020: 14 · 2019: 17 · 2018: 15 · 2017: 11 · 2016: 18 · 2015: 16 · 2014: 17 · 2013: 23 · 2012: 14
- FWCI
- 8.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 3001 d)
- Locations
- The American Journal of Human Genetics (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- BORIS (University Library Bern) (submittedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM073020, R01GM73020)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK037922, K01DK002939, KO1 DK02939, R01DK37922)
- National Institute of Dental and Craniofacial Research (P60DE013078)
- National Center for Research Resources (M01 RR-00052, M01RR000052)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01 HD41958, R01HD041958)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- cytochrome P450 oxidoreductase, Antley-Bixler syndrome, ambiguous genitalia, FGFR2 mutations, FGFR3 mutation, missense mutations, frameshift mutation, genotype-phenotype correlation, P450c17, 17α-hydroxylase, 17,20-lyase, NADPH oxidation, cytochrome c reduction
- MeSH terms
- Abnormalities, Multiple, Amino Acid Sequence, Craniosynostoses, Female, Genitalia, Humans, Infant, Infant, Newborn, Male, Models, Molecular, Molecular Sequence Data, Mutation, NADPH-Ferrihemoprotein Reductase, Steroids, Syndrome, Genetic Variation, Sequence Alignment, Receptors, Fibroblast Growth Factor, Receptor Protein-Tyrosine Kinases, Receptor, Fibroblast Growth Factor, Type 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.